Rapiscan (regadenoson) injection

SECTION 2: Hazards identification

Emergency overview Material intended for pharmaceutical research, manufacturing, and clinical uses only. Dosage form contains CVT-3146, a pharmaceutically active material intended for research and clinical use only. Dosage form contents may pose a health hazard only if exposure occurs to contents, eg, after spill or leak. Overexposure may affect the cardiovascular system and the central nervous system. Symptoms may include increased heart rate, palpitations, flushing, nausea, hyperventilation, and headache. Avoid ingestion, inhalation, skin and eye contact. Routes of absorption Presumed inhalation, ingestion, eye and skin absorption. Acute effects Skin: No data available Eye: No data available Inhalation: If inhaled, may cause effects similar to those described under Target organs. Ingestion: No data available Target organs/ Patients administered the drug intravenously have shown effects related to systemic toxicity the pharmacological effects of the drug on the cardiovascular system with symptoms including increased heart rate, palpitations, flushing, nausea, hyperventilation, and headache. Reproductive/ No data available developmental toxicity Mutagenicity and CVT-3146 is not considered a mutagen based on standard battery of studies carcinogenicity (see Section 11). Occupational None established by ACGIH, OSHA, or NIOSH. exposure limit

Medical Conditions Generally Aggravated by Exposure

Not known